Jessy Warner-Cohen

Jessy Warner-Cohen

Auto-generated profile, based on publicly available information

Jessy Warner-Cohen

Northwell Health Cancer Institute Northwell Health New York New York USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2005 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
RSRobert C Smith
Robert C Smith
JWJessy Warner-Cohen
Jessy Warner-Cohen
MMMelissa Matute
Melissa Matute
EBErin Butler
Erin Butler
EKErin Kelly
Erin Kelly
AKAlea Khan
Alea Khan
Schizophrenics have among the highest rates of cigarette smoking. Some studies indicate that cigarette smoking or nicotine may ameliorate some of the cognitive or theoretically related neurophysiological deficits seen in schizophrenic patients. This study investigated the effects of nicotine nasal spray on measures of attention, verbal memory, and visual–spatial memory in schizophrenic patients who were chronic smokers, using a double-blind placebo-controlled pre–post experimental design. Compared to placebo, active nicotine spray significantly decreased reaction time on the Conner's CPT and improved scores on a measure purported to reflect spatial working memory on a dot task. There were trends for the increased number of hits and decreased number of errors in pre–post comparisons on the CPT task in the active nicotine session. There were no effects of active nicotine nasal spray on verbal memory. Our results suggest that nicotine may modestly enhance attention and spatial working memory in schizophrenic patients who are cigarette smokers and have been abstinent overnight.

1 January 1999 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
RSRobert C. Smith
Robert C. Smith
JLJean-Pierre Lindenmayer
Jean-Pierre Lindenmayer
NBNigel Bark
Nigel Bark
JWJessy Warner-Cohen
Jessy Warner-Cohen
SVSumathi Vaidhyanathaswamy
Sumathi Vaidhyanathaswamy
AKAmaresh Khandat
Amaresh Khandat
Some reports have indicated increased rates of diabetes and increased prevalence of glucose and lipid abnormalities during treatment with second-generation antipsychotics, with most concern raised about clozapine and olanzapine. Most of the findings have come from case reports, retrospective examination of laboratory values, and analysis of health-care claims databases. This study investigated fasting levels of glucose, lipids, and leptin in a non-randomized, cross- sectional study of 210 patients, with schizophrenic or schizoaffective disorder, treated with a single antipsychotic medication – clozapine, risperidone, olanzapine, or a conventional antipsychotic. Glucose tolerance tests (GTT), with a 75-g glucose load, were preformed in a subset of patients. In this sample most mean fasting glucose and lipid levels were within the normal range and were not significantly different across the four drug treatment groups. Patients treated with clozapine and olanzapine had higher triglyceride levels than risperidone patients. In patients receiving a GTT, risperidone-treated patients had higher glucose levels at 1 h than patients treated with olanzapine, and there were more patients on risperidone who met American Diabetes Association glucose metabolic criteria for diagnosis of diabetes. Although there were no significant differences in age or body mass index among the four drug groups, we cannot rule out some potential biasing factors we did not assess which could potentially influence our results. These include unknown physician preference in drug selection based on their beliefs about the weight-inducing or diabetes potential of different antipsychotics, differences in visceral fat, and differences in patients' antipsychotic drug history.

11 August 2018 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
LSLIRON SINVANI
LIRON SINVANI
JWJessy Warner‐Cohen
Jessy Warner‐Cohen
ASAndrew Strunk
Andrew Strunk
THTravis Halbert
Travis Halbert
RHRuchika Harisingani
Ruchika Harisingani
CKCorey Karlin‐Zysman
Corey Karlin‐Zysman

5 June 2018 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
ACAubrey C. Chan
Aubrey C. Chan
CBChristopher A. Burke
Christopher A. Burke
ECEllen M. Coffey
Ellen M. Coffey
DHDavid R. Hilden
David R. Hilden
DCDiego L. Coira
Diego L. Coira
GSGen Shinozaki
Gen Shinozaki

20 July 2020 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
JWJessy Warner‐Cohen
Jessy Warner‐Cohen
APAshley R. Polokowski
Ashley R. Polokowski
DPDanielle Pinto
Danielle Pinto
TZTiffany Zavadsky
Tiffany Zavadsky
KBKristen Beyer
Kristen Beyer
MWMatthew J. Weiss
Matthew J. Weiss